Switch to
More onapp

How to use scorecard? Learn more

Supriya Lifescience Ltd

SUPRIYA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,398 cr, stock is ranked 806
High RiskStock is 3.50x as volatile as Nifty
545.750.75 (-0.14%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,398 cr, stock is ranked 806
High RiskStock is 3.50x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
32.53
PB RatioPB Ratio
6.29
Dividend YieldDiv. Yield
0.15%
Sector PESector PE
49.93
Sector PBSector PB
6.39
Sector Div YldSctr Div Yld
0.52%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Supriya Lifescience is a manufacturer of pharmaceutical preparation.

Financial TrendFinancial statements 

2021202220232024396.22537.63470.43581.01123.60151.8189.86119.12
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Reply to Clarification- Financial results 
Announced OnAug 27, 2024

The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed. | Download

The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed. | Download

Clarification - Financial Results 
Announced OnAug 22, 2024
The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Cash Dividend 
Ex. DateSep 15, 2023

Final • Div/Share: ₹ 0.6

See all events